Emerging role of endosomal toll-like receptors in rheumatoid arthritis

Frontiers in Immunology

Volumn 5, Issue JAN, 2014, Pages

  Thwaites, Ryan ^a   Chamberlain, Giselle ^a   Sacre, Sandra ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Autoimmunity; Autoimmunity models; Endosomal toll like receptors; Inflammation; Rheumatoid arthritis; Therapeutics; Toll like receptor

Indexed keywords

TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE COURSE; GENE SILENCING; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPLEEN CELL;

EID: 84895524861     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00001     Document Type: Review

References (81)

1. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol (2004) 4(7):499-511. doi:10.1038/nri1391.
2. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem (2004) 279(9):7370-7. doi:10.1074/jbc.M306793200.
3. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med (2009) 15(7):774-80. doi:10.1038/nm.1987.
4. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm (2010) 2010:672395. doi:10.1155/2010/672395.
5. Barbalat R, Ewald SE, Mouchess ML, Barton GM. Nucleic acid recognition by the innate immune system. Annu Rev Immunol (2011) 29:185-214. doi:10.1146/annurev-immunol-031210-101340.
6. Li Y, Berke IC, Modis Y. DNA binding to proteolytically activated TLR9 is sequence-independent and enhanced by DNA curvature. EMBO J (2012) 31(4):919-31. doi:10.1038/emboj.2011.441.
7. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol (2006) 117(5):979-87. doi:10.1016/j.jaci.2006.02.023.
8. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell (1996) 85(3):307-10. doi:10.1016/S0092-8674(00)81109-5.
9. Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac'h N, Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun (2012) 39(3):222-8. doi:10.1016/j.jaut.2012.05.021.
10. Lee DG, Woo JW, Kwok SK, Cho ML, Park SH. MRP8 promotes Th17 differentiation via upregulation of IL-6 production by fibroblast-like synoviocytes in rheumatoid arthritis. Exp Mol Med (2013) 45:e20. doi:10.1038/emm.2013.39.
11. Davignon JL, Hayder M, Baron M, Boyer JF, Constantin A, Apparailly F, et al. Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2013) 52(4):590-8. doi:10.1093/rheumatology/kes304.
12. Moncur C, Williams HJ. Rheumatoid arthritis: status of drug therapies. Phys Ther (1995) 75(6):511-25.
13. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol (2002) 2(5):364-71. doi:10.1038/nri802.
14. Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol (2013) 9(3):154-63. doi:10.1038/nrrheum.2013.8.
15. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther (2011) 13(Suppl 1):S5. doi:10.1186/1478-6354-13-S1-S5.
16. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther (2009) 11(Suppl 1):S1. doi:10.1186/ar2666.
17. Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis (2012) 71(3):351-7. doi:10.1136/annrheumdis-2011-200170.
18. Alessandri C, Scrivo R, Spinelli FR, Ceccarelli F, Magrini L, Priori R, et al. Autoantibody production in anti-TNF-alpha-treated patients. Ann N Y Acad Sci (2007) 1110:319-29. doi:10.1196/annals.1423.034.
19. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis (2008) 67(11):1516-23. doi:10.1136/ard.2008.092932.
20. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van derHeijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum (2005) 52(4):1020-30. doi:10.1002/art.20982.
21. Binder NB, Puchner A, Niederreiter B, Hayer S, Leiss H, Blüml S, et al. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. Arthritis Rheum (2013) 65(3):608-17. doi:10.1002/art.37797.
22. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum (2005) 34(6):819-36. doi:10.1016/j.semarthrit.2004.11.006.
23. Kontzias A, Laurence A, Gadina M, O'Shea JJ. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep (2012) 4:5. doi:10.3410/M4-5.
24. Cutolo M. The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis (2013) 5(1):3-11. doi:10.1177/1759720X12470753.
25. Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis (2008) 67(7):909-16. doi:10.1136/ard.2007.074278.
26. Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med (1981) 154(3):688-700. doi:10.1084/jem.154.3.688.
27. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, Radstake TR, Matera G, Popa C, et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum (2007) 56(9):2957-67. doi:10.1002/art.22848.
28. Rosenzweig HL, Jann MJ, Vance EE, Planck SR, Rosenbaum JT, Davey MP. Nucleotide-binding oligomerization domain 2 and Toll-like receptor 2 function independently in a murine model of arthritis triggered by intraarticular peptidoglycan. Arthritis Rheum (2010) 62(4):1051-9. doi:10.1002/art.27335.
29. Meng L, Zhu W, Jiang C, He X, Hou W, Zheng F, et al. Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats. Arthritis Res Ther (2010) 12(3):R103. doi:10.1186/ar3034.
30. Zhu W, Meng L, Jiang C, Xu J, Wang B, Han Y, et al. Overexpression of toll-like receptor 3 in spleen is associated with experimental arthritis in rats. Scand J Immunol (2012) 76(3):263-70. doi:10.1111/j.1365-3083.2012.02724.x.
31. Zhu W, Meng L, Jiang C, He X, Hou W, Xu P, et al. Arthritis is associated with T-cell-induced upregulation of Toll-like receptor 3 on synovial fibroblasts. Arthritis Res Ther (2011) 13(3):R103. doi:10.1186/ar3384.
32. Yarilina A, DiCarlo E, Ivashkiv LB. Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J Immunol (2007) 178(4):2204-11.
33. Hayashi T, Gray CS, Chan M, Tawatao RI, Ronacher L, McGargill MA, et al. Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc Natl Acad Sci U S A (2009) 106(8):2764-9. doi:10.1073/pnas.0813037106.
34. Alzabin S, Kong P, Medghalchi M, Palfreeman A, Williams R, Sacre S. Investigation of the role of endosomal Toll-like receptors in murine collagen-induced arthritis reveals a potential role for TLR7 in disease maintenance. Arthritis Res Ther (2012) 14(3):R142. doi:10.1186/ar3875.
35. Chen SY, Shiau AL, Li YT, Lin YS, Lee CH, Wu CL, et al. Suppression of collagen-induced arthritis by intra-articular lentiviral vector-mediated delivery of Toll-like receptor 7 short hairpin RNA gene. Gene Ther (2012) 19(7):752-60. doi:10.1038/gt.2011.173.
36. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 303(5663):1526-9. doi:10.1126/science.1093620.
37. Demaria O, Pagni PP, Traub S, de Gassart A, Branzk N, Murphy AJ, et al. TLR8 deficiency leads to autoimmunity in mice. J Clin Invest (2010) 120(10):3651-62. doi:10.1172/JCI42081.
38. Radic M, Marion T, Monestier M. Nucleosomes are exposed at the cell surface in apoptosis. J Immunol (2004) 172(11):6692-700.
39. Miles K, Heaney J, Sibinska Z, Salter D, Savill J, Gray D, et al. A tolerogenic role for Toll-like receptor 9 is revealed by B-cell interaction with DNA complexes expressed on apoptotic cells. Proc Natl Acad Sci U S A (2012) 109(3):887-92. doi:10.1073/pnas.1109173109.
40. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet (2004) 75(2):330-7. doi:10.1086/422827.
41. Wang Y, Stanford S, Zhou W, Auger Jennifer L, Cheng G, Campbell A, et al. Rheumatoid arthritis-associated PTPN22 modulates toll-like receptor-mediated, type 1 interferon-dependent innate immunoregulation [abstract]. Arthritis Rheum (2012) 64(Suppl 10):2452. doi:10.1002/art.40183.
42. Han SW, Lee WK, Kwon KT, Lee BK, Nam EJ, Kim GW. Association of polymorphisms in interferon regulatory factor 5 gene with rheumatoid arthritis: a metaanalysis. J Rheumatol (2009) 36(4):693-7. doi:10.3899/jrheum.081054.
43. van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater-Zyberk C, Vervoordeldonk MJ, et al. Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther (2004) 6(3):R239-49. doi:10.1186/ar1165.
44. Vervoordeldonk MJ, Aalbers CJ, Tak PP. Interferon beta for rheumatoid arthritis: new clothes for an old kid on the block. Ann Rheum Dis (2009) 68(2):157-8. doi:10.1136/ard.2008.097899.
45. Herman S, Fischer A, Pfatschbacher J, Hoffmann M, Steiner G. A TLR 9 antagonist diminishes arthritis severity in a rat model of rheumatoid arthritis. Ann Rheum Dis (2011) 70(Suppl 2):A39. doi:10.1136/ard.2010.148973.8.
46. Kawane K, Tanaka H, Kitahara Y, Shimaoka S, Nagata S. Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation. Proc Natl Acad Sci U S A (2010) 107(45):19432-7. doi:10.1073/pnas.1010603107.
47. Paulsen F, Pufe T, Conradi L, Varoga D, Tsokos M, Papendieck J, et al. Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes. J Pathol (2002) 198(3):369-77. doi:10.1002/path.1224.
48. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 25(3):417-28. doi:10.1016/j.immuni.2006.07.013.
49. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med (2005) 202(8):1131-9. doi:10.1084/jem.20050914.
50. Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum (2010) 62(3):683-93. doi:10.1002/art.27304.
51. Hoffmann MH, Skriner K, Herman S, Baumann C, Steiner CW, Ospelt C, et al. Nucleic acid-stimulated antigen-presenting cells trigger T cells to induce disease in a rat transfer model of inflammatory arthritis. J Autoimmun (2011) 36(3-4):288-300. doi:10.1016/j.jaut.2011.02.007.
52. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 42(6):508-14. doi:10.1038/ng.582.
53. Coenen MJ, Enevold C, Barrera P, Schijvenaars MM, Toonen EJ, Scheffer H, et al. Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcome. PLoS One (2010) 5(12):e14326. doi:10.1371/journal.pone.0014326.
54. Jaen O, Petit-Teixeira E, Kirsten H, Ahnert P, Semerano L, Pierlot C, et al. No evidence of major effects in several Toll-like receptor gene polymorphisms in rheumatoid arthritis. Arthritis Res Ther (2009) 11(1):R5. doi:10.1186/ar2589.
55. Etem EO, Elyas H, Ozgocmen S, Yildirim A, Godekmerdan A. The investigation of toll-like receptor 3, 9 and 10 gene polymorphisms in Turkish rheumatoid arthritis patients. Rheumatol Int (2011) 31(10):1369-74. doi:10.1007/s00296-010-1472-8.
56. Enevold C, Radstake TR, Coenen MJ, Fransen J, Toonen EJ, Bendtzen K, et al. Multiplex screening of 22 single-nucleotide polymorphisms in 7 Toll-like receptors: an association study in rheumatoid arthritis. J Rheumatol (2010) 37(5):905-10. doi:10.3899/jrheum.090775.
57. Sacre SM, Andreakos E, Kiriakidis S, Amjadi P, Lundberg A, Giddins G, et al. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol (2007) 170(2):518-25. doi:10.2353/ajpath.2007.060657.
58. Sacre SM, Lo A, Gregory B, Simmonds RE, Williams L, Feldmann M, et al. Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures. J Immunol (2008) 181(11):8002-9.
59. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum (2005) 52(9):2656-65. doi:10.1002/art.21273.
60. Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, et al. Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum (2008) 58(12):3684-92. doi:10.1002/art.24140.
61. Tamaki Y, Takakubo Y, Hirayama T, Konttinen YT, Goodman SB, Yamakawa M, et al. Expression of Toll-like receptors and their signaling pathways in rheumatoid synovitis. J Rheumatol (2011) 38(5):810-20. doi:10.3899/jrheum.100732.
62. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen FH, et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum (2005) 52(8):2313-22. doi:10.1002/art.21278.
63. Hu F, Mu R, Zhu J, Shi L, Li Y, Liu X, et al. Hypoxia and hypoxia-inducible factor-1alpha provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis. Ann Rheum Dis (2013). doi:10.1136/annrheumdis-2012-202444.
64. Moon SJ, Park MK, Oh HJ, Lee SY, Kwok SK, Cho ML, et al. Engagement of toll-like receptor 3 induces vascular endothelial growth factor and interleukin-8 in human rheumatoid synovial fibroblasts. Korean J Intern Med (2010) 25(4):429-35. doi:10.3904/kjim.2010.25.4.429.
65. Kim KW, Cho ML, Oh HJ, Kim HR, Kang CM, Heo YM, et al. TLR-3 enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis. Immunol Lett (2009) 124(1):9-17. doi:10.1016/j.imlet.2009.02.006.
66. Veiko NN, Shubaeva NO, Ivanova SM, Speranskii AI, Lyapunova NA, Spitkovskii DM. Blood serum DNA in patients with rheumatoid arthritis is considerably enriched with fragments of ribosomal repeats containing immunostimulatory CpG-motifs. Bull Exp Biol Med (2006) 142(3):313-6. doi:10.1007/s10517-006-0354-2.
67. Lai Y, Adhikarakunnathu S, Bhardwaj K, Ranjith-Kumar CT, Wen Y, Jordan JL, et al. LL37 and cationic peptides enhance TLR3 signaling by viral double-stranded RNAs. PLoS One (2011) 6(10):e26632. doi:10.1371/journal.pone.0026632.
68. Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med (2009) 206(9):1983-94. doi:10.1084/jem.20090480.
69. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 449(7162):564-9. doi:10.1038/nature06116.
70. Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum (1987) 16(3):206-21. doi:10.1016/0049-0172(87)90023-0.
71. Khraishi MM, Singh G. The role of anti-malarials in rheumatoid arthritis-the American experience. Lupus (1996) 5(Suppl 1):S41-4. doi:10.1177/096120339600500110.
72. Sanjuan MA, Rao N, Lai KT, Gu Y, Sun S, Fuchs A, et al. CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J Cell Biol (2006) 172(7):1057-68. doi:10.1083/jcb.200508058.
73. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol (2011) 186(8):4794-804. doi:10.4049/jimmunol.1000702.
74. VentiRx. TLR8 Antagonist. (2013) [cited 2013 Oct 18]. Available from: http://www.ventirx.com/product/tlr8-antagonist.htm.
75. Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev (2000) 4:CD000959. doi:10.1002/14651858.CD000959.
76. Park SJ, Lee AN, Youn HS. TBK1-targeted suppression of TRIF-dependent signaling pathway of toll-like receptor 3 by auranofin. Arch Pharm Res (2010) 33(6):939-45. doi:10.1007/s12272-010-0618-2.
77. Lipford G, Forsbach A, Zepp C, Nguyen T, Weeratna R, McCluskie M, et al. Selective toll-like receptor 7/8/9 antagonists for the oral treatment of autoimmune diseases. American College of Rheumatology Annual Scientific Meeting 2007 (2007).
78. Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature (2010) 465(7300):937-41. doi:10.1038/nature09102.
79. Dynavax. Pipeline: Autoimmunity/Inflammation. (2013) [cited 2013 Oct 18]. Available from: http://www.dynavax.com/autoimmunity.html.
80. Idera. Clinical Programs: Overview. (2013) [cited 2013 Oct 18]. Available from: http://www.iderapharma.com/clinical-trials.
81. Kandimalla ER, Bhagat L, Wang D, Yu D, Sullivan T, La Monica N, et al. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res (2013) 41(6):3947-61. doi:10.1093/nar/gkt078.